home / stock / lci / lci news


LCI News and Press, Lannett Co Inc From 11/02/22

Stock Information

Company Name: Lannett Co Inc
Stock Symbol: LCI
Market: NYSE

Menu

LCI LCI Quote LCI Short LCI News LCI Articles LCI Message Board
Get LCI Alerts

News, Short Squeeze, Breakout and More Instantly...

LCI - LANNETT REPORTS BETTER THAN EXPECTED FINANCIAL RESULTS FOR FISCAL 2023 FIRST-QUARTER; REITERATES FULL-YEAR GUIDANCE

LANNETT REPORTS BETTER THAN EXPECTED FINANCIAL RESULTS FOR FISCAL 2023 FIRST-QUARTER; REITERATES FULL-YEAR GUIDANCE PR Newswire Q1 Business and Financial Highlights: Net Sales were $75.1 Million Gross Margin 17%, Adjusted Gross Margin 18% ...

LCI - LANNETT TO REPORT FISCAL 2023 FIRST-QUARTER FINANCIAL RESULTS, HOST CONFERENCE CALL ON WEDNESDAY, NOVEMBER 2

LANNETT TO REPORT FISCAL 2023 FIRST-QUARTER FINANCIAL RESULTS, HOST CONFERENCE CALL ON WEDNESDAY, NOVEMBER 2 PR Newswire TREVOSE, Pa. , Oct. 26, 2022 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today announced that it will report financial results f...

LCI - Lannett gets FDA approval to manufacture Numbrino® at Seymour plant

The U.S. Food and Drug Administration (FDA) approved micro-cap generic drugmaker Lannett Company ( NYSE: LCI ) to rapidly expand liquid drug manufacturing of Numbrino ® , the company's branded topical anesthetic product, at its main plant in Seymour, Indiana...

LCI - LANNETT RECEIVES FDA APPROVAL TO MANUFACTURE NUMBRINO® AT SEYMOUR PLANT

LANNETT RECEIVES FDA APPROVAL TO MANUFACTURE NUMBRINO® AT SEYMOUR PLANT PR Newswire --Approval Allows Site to Rapidly Expand Liquid Drug Manufacturing-- PHILADELPHIA , Oct. 21, 2022 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today ...

LCI - LANNETT ANNOUNCES SALE OF SEVERAL DISCONTINUED GENERIC DRUGS

LANNETT ANNOUNCES SALE OF SEVERAL DISCONTINUED GENERIC DRUGS PR Newswire -Companies Entered Into a Separate Private Label Agreement for Certain Other Lannett Generic Products- PHILADELPHIA , Oct. 19, 2022 /PRNewswire/ -- Lannett Company, Inc. ...

LCI - LANNETT ANNOUNCES SUBJECT DOSING COMPLETE FOR PIVOTAL CLINICAL TRIAL OF BIOSIMILAR INSULIN GLARGINE

LANNETT ANNOUNCES SUBJECT DOSING COMPLETE FOR PIVOTAL CLINICAL TRIAL OF BIOSIMILAR INSULIN GLARGINE PR Newswire No Reported Serious Adverse Events; Topline Results Expected Later This Year TREVOSE, Pa. , Aug. 31, 2022 /PRNewswire/ -- Lannett C...

LCI - Lannett Company, Inc. (LCI) CEO Timothy Crew on Q4 2022 Results - Earnings Call Transcript

Lannett Company, Inc. (LCI) Q4 2022 Earnings Conference Call August 24, 2022 04:30 PM ET Company Participants Robert Jaffe - Investor Relations, Robert Jaffe Co., LLC Timothy Crew - Chief Executive Officer John Kozlowski - Chief Financial Officer Conference...

LCI - Lannett GAAP EPS of -$2.30, revenue of $74.19M

Lannett press release ( NYSE: LCI ): Q4 GAAP EPS of -$2.30; Non-GAAP EPS of -$0.44 Revenue of $74.19M (-30.0% Y/Y). Adjusted gross profit was $10.4 million, or 14% of net sales, compared with $26.4 million, or 25% of net sales. Negative adjusted EBITDA was $1.3 mil...

LCI - LANNETT REPORTS FISCAL 2022 FOURTH-QUARTER, FULL-YEAR FINANCIAL RESULTS

LANNETT REPORTS FISCAL 2022 FOURTH-QUARTER, FULL-YEAR FINANCIAL RESULTS PR Newswire Q4 Business and Financial Highlights: Net Sales were $74.2 Million Adjusted Gross Margin Better than Expected, Improved vs Q3 Cash Was $88 Million at ...

LCI - LANNETT TO REPORT FISCAL 2022 FOURTH-QUARTER, FULL-YEAR FINANCIAL RESULTS, HOST CONFERENCE CALL ON WEDNESDAY, AUGUST 24

LANNETT TO REPORT FISCAL 2022 FOURTH-QUARTER, FULL-YEAR FINANCIAL RESULTS, HOST CONFERENCE CALL ON WEDNESDAY, AUGUST 24 PR Newswire TREVOSE, Pa. , Aug. 19, 2022 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today announced that it will report financia...

Previous 10 Next 10